NASDAQ · MIST
Milestone Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MIST: Nov 11, 2026
Milestone Pharmaceuticals Inc. Common Shares is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.16 | $-0.22 | 4 |
| Dec 2026 | $-0.22 | $-0.20 | $-0.23 | 4 |
| Mar 2027 | $-0.23 | $-0.23 | $-0.23 | 2 |
| Jun 2027 | $-0.23 | $-0.23 | $-0.24 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · MarketBeat- Fintel · Oct 29, 2:58 AM EDTMilestone Pharmaceuticals Inc. Receives Nasdaq Notice of Non-Compliance Under Rule 5450(a)(1)On October 23, 2026, Milestone Pharmaceuticals Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common shares was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued list
- RTTNews · Oct 9, 9:39 AM EDTSagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks(RTTNews) – Sagimet Biosciences Inc. (SGMT) announced positive 52-week results from a Phase 3 open-label extension study of denifanstat in patients with moderate-to-severe acne vulgaris. The data, generated by its license partner Ascletis BioScience in China, will be presented at
- RTTNews · Oct 9, 9:19 AM EDTMilestone Moves Etripamil AFib-RVR Program Forward With First European Patient; Stock Up(RTTNews) – Milestone Pharmaceuticals Inc. (MIST) announced that the first European patient has been enrolled in its Phase 3 ReVeRA-301 clinical trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR). The patient was enrolled at a si
- RTTNews · Sep 27, 8:28 AM EDTMilestone Enrolls First Canadian Patient In Phase 3 For Etripamil(RTTNews) – Milestone Pharmaceuticals Inc. (MIST), a biopharmaceutical company, on Friday announced the enrollment of the first patient in the Canadian site of the Phase 3 ReVeRA-301 trial evaluating the Etripamil nasal spray for treating atrial fibrillation with rapid ventricula
- RTTNews · Sep 4, 10:09 AM EDTWeekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) – This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring moves. Ionis, Milestone, Novavax advanced key programs, while United Imaging gaine
- RTTNews · Sep 3, 11:19 AM EDTMilestone Gets China Approval For Etripamil Nasal Spray(RTTNews) – Milestone Pharmaceuticals (MIST) on Thursday announced that China's National Medical Products Administration has approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. Etripamil is marketed in the U.S. as CARDAMYST.
- RTTNews · Sep 3, 10:31 AM EDTMilestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT(RTTNews) – Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that the China National Medical Products Administration (NMPA) has approved CARDAMYST (Etripamil) nasal spray for the treatment of paroxysmal supraventricular tachycardia.
- RTTNews · Sep 3, 9:57 AM EDTMilestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment(RTTNews) – Milestone Pharmaceuticals Inc. (MIST) announced that China's National Medical Products Administration has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adults. The NMPA decision marks the first regulatory approval of e
- RTTNews · Aug 21, 8:18 AM EDTMilestone Initiates Phase 3 Trial Of Etripamil For Self-Administered AFib-RVR Treatment(RTTNews) – Milestone Pharmaceuticals Inc. (MIST), an emerging commercial-stage biopharmaceutical company focused on cardiovascular medicines, announced the initiation of its pivotal Phase 3 ReVeRA-301 trial evaluating etripamil nasal spray for the self-administered treatment of
- The Motley Fool · Aug 19, 9:29 AM EDTMilestone (MIST) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 11:04 AM EDTMilestone Pharmaceuticals Q2 Earnings Call HighlightsMilestone Pharmaceuticals (NASDAQ:MIST) reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR. Chief Executive Officer Joseph Oliv
- RTTNews · Aug 12, 9:37 AM EDTMilestone Q2 Net Loss Expands; ReVeRA-301 Phase 3 Trial Of Etripamil Open For Enrollment; Stock Down(RTTNews) – Milestone Pharmaceuticals Inc. (MIST), a biopharmaceutical company, announced financial results for the second quarter, reflecting a wider net loss and provided an update on its regulatory and clinical programs.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Milestone Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.